Orexin-2 Receptor Agonist for Narcolepsy Enters Phase 2 Trials
The phase 2 trial will evaluate the safety and efficacy of ALKS 2680, a novel orexin-2 receptor agonist, in patients with narcolepsy type 1.
Source: sleepreviewmag.com
Test Efficacy News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Test Efficacy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Test Efficacy Today - Breaking & Trending Today
The NYSPCC Receives $1.65 Million in Grants for Programs that Advance Agency's Mission to Prevent Child Abuse
/PRNewswire/ -- The New York Society for the Prevention of Cruelty to Children (NYSPCC), the world's first child protection agency, has received $1.65 million...
Source: prnewswire.com
Myasthenia Gravis Treatment Landscape Rapidly Evolving
Approximately 70 to 300 million individuals worldwide are living with myasthenia gravis, an antibody-mediated autoimmune disorder that adversely affects neuromuscular junction function.
Source: ajmc.com
UCB : Presents Latest Data from Generalized Myasthenia Gravis Portfolio at 9th Congress of the European Academy of Neurology (EAN) Meeting
UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio at 9th Congress of the European Academy of Neurology Meeting Results presented across...
Source: marketscreener.com
UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review
Biologic License Application (BLA) designated Priority Review by FDA and seeks approval for rozanolixizumab for the treatment of adults with generalized...
Source: prnewswire.com